Steven Smith
Directeur des opérations chez AshHill Investments LLC
Profil
Steven R Smith is currently the Chief Operating Officer at AshHill Investments LLC and a Partner at Cincinnati.
He was previously a Board Member at Heart Metabolics Ltd.
Smith received an undergraduate degree from the University of Cincinnati and a graduate degree from the University of Dayton School of Law.
Postes actifs de Steven Smith
| Sociétés | Poste | Début |
|---|---|---|
AshHill Investments LLC
 AshHill Investments LLC Investment ManagersFinance AshHill Investments LLC (AshHill Investments) is a venture capital firm founded in 2011. The firm is headquartered in Ft. Thomas, Kentucky. | Directeur des opérations | - |
| Cincinnati | Private Equity Investor | - |
Anciens postes connus de Steven Smith
| Sociétés | Poste | Fin |
|---|---|---|
Heart Metabolics Ltd.
 Heart Metabolics Ltd. BiotechnologyHealth Technology Heart Metabolics Ltd. operates as a biopharmaceutical company that engages in developing new treatments for orphan disease including cardio-metabolic diseases. The firm provides drugs to treat heart failure for hypertrophic cardiomyopathy patients. The company was founded by Michael Paul Frenneaux and Houshman Ashrafian in 2004 and is headquartered in Dublin, Ireland. | Directeur/Membre du Conseil | - |
Formation de Steven Smith
| University of Cincinnati (Ohio) | Undergraduate Degree |
| University of Dayton School of Law | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
AshHill Investments LLC
AshHill Investments LLC Investment ManagersFinance AshHill Investments LLC (AshHill Investments) is a venture capital firm founded in 2011. The firm is headquartered in Ft. Thomas, Kentucky. | Finance |
Heart Metabolics Ltd.
Heart Metabolics Ltd. BiotechnologyHealth Technology Heart Metabolics Ltd. operates as a biopharmaceutical company that engages in developing new treatments for orphan disease including cardio-metabolic diseases. The firm provides drugs to treat heart failure for hypertrophic cardiomyopathy patients. The company was founded by Michael Paul Frenneaux and Houshman Ashrafian in 2004 and is headquartered in Dublin, Ireland. | Health Technology |
| Cincinnati | Finance |
